ArticleTherapeutic advances in medical oncology2024

Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience.

Shenyu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.